Etanercept reduces hyperalgesia in experimental painful neuropathy.
ABSTRACT Etanercept, a recombinant tumor necrosis factor receptor (p75)-Fc fusion protein competitively inhibits tumor necrosis factor-alpha (TNF). Etanercept has been successfully used in patients with rheumatoid arthritis, where it reduces pain and inflammation. Because locally produced proinflammatory cytokines play a role in pain after nerve injury, we investigated whether etanercept can reduce pain and hyperalgesia in an animal model of painful neuropathy, the chronic constriction injury of the sciatic nerve. C57BL/6 mice received etanercept or sham treatment by local near-nerve injection to the injured nerve or by systemic application. Treatment with etanercept reduced thermal hyperalgesia and mechanical allodynia significantly in both modes of application. The effect of etanercept was present in animals that were treated from the time of surgery and in those that were treated from day 6, when hyperalgesia was already present. These results suggest the potential of etanercept as a treatment option for patients with neuropathic pain.
SourceAvailable from: Leo A B Joosten
CNS Drugs 11/2014; DOI:10.1007/s40263-014-0212-0 · 4.38 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Musculoskeletal pain, a major public health problem, is understudied pre-clinically.•Local intramuscular injections of acidified saline model facets of musculoskeletal pain.•IL-1 and IL-6, but not TNF, increase in muscle after injection of acidified saline.•Inhibiting NFκB in muscle blocks allodynia after acidified saline injection.•IL-1 receptor KO mice and IL-6 KO mice do not develop allodynia in this model.Brain Behavior and Immunity 10/2014; DOI:10.1016/j.bbi.2014.10.009 · 5.61 Impact Factor